Novlead Biotech Debuts Gas Detection Portfolio at CACLP 2024 Amid Hong Kong IPO Filing

March 17,Noliving Biotech showcased its Reslink electrochemical exhaled nitric oxide analyzer, the first domestically produced chemiluminescence-based exhaled nitric oxide detection platform, and a new-generation portable optical platform for end-tidal carbon monoxide (ETCO) at the CACLP Instruments and Reagents Exhibition Area – Central Hall.

Amidst the dazzling array of chemiluminescence systems, laboratory automation lines, and classic laboratory equipment in the central hall exhibition area, Noliving Biotech, as the “one-of-a-kind” gas detection and therapy platform, captured the attention of numerous diagnostics industry professionals on site with its distinctive booth design and unique product style upon its debut.

In April 2022, Noliving Biotech launched INOwill, China’s first on-demand nitric oxide therapy device. Utilizing electrochemical catalysis to generate high-purity nitric oxide gas instantly, INOwill eliminates the need for bulky and cumbersome gas cylinders. It ensures rapid, precise, and sustained gas delivery while featuring breath-synchronized tracking and real-time dynamic monitoring, thereby guaranteeing safe and reliable clinical treatment. To date, INOwill has been installed or is undergoing trials in more than 300 hospitals.

iNOwill Series – China’s First On-Demand Nitric Oxide Therapy Device

While continuing to strengthen its core therapeutic platform, Noliving Biotech has also established a multi-methodological, continuously iterated product portfolio in the field of multi-gas detection and diagnostics.The newly unveiled products offer new perspectives for clinical applications in multiple fields, including the diagnosis and assessment of airway inflammation such as asthma (using electrochemical and chemiluminescence methods), red blood cell lifespan measurement (optical method), and neonatal jaundice management (optical method). These solutions cover departments such as Respiratory Medicine, Neonatology/Pediatrics, Otolaryngology, Allergy, Hematology, Nephrology, and Health Check-up Centers.

Staff members from the Noliving Biotech booth told VCBeat in an interview that“In 2024, Noliving Biotech’s detection line is expected to have multiple self-developed instruments approved for market launch. This marks a new development in our exclusive, full-industry-chain layout for the clinical application of medical-grade nitric oxide (NO) gas in China, further establishing a comprehensive ecosystem for the clinical use of medical-grade NO gas.”

As a technology-platform medical enterprise specializing in nitric oxide (NO) gas detection and therapy, the Noliving Biotech team will remain true to its original aspiration, continuing to dedicate itself to the R&D of innovative pipelines, addressing unmet clinical needs, and advancing the global adoption of NO therapy. Meanwhile, the team also aims to drive the development of China’s high-end manufacturing through innovative products, ensuring that China’s original scientific and technological innovations benefit the world.

Noliving Biotech is the first technology-platform enterprise in China dedicated to nitric oxide gas therapy and multi-gas detection. Leveraging its internationally competitive, self-developed technologies for instantaneous generation and controlled slow release of nitric oxide, as well as composite sensing for multiple gases, the company focuses on the R&D of innovative medical devices, providing breakthrough clinical solutions for cardiopulmonary, respiratory, immune, and anti-infective fields.